Treating breast cancer in the 21st century: Emerging biological therapies

Gabriel Tinoco, Sean Warsch, Stefan Glück, Kiran Avancha, Alberto J. Montero

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

For many years, the medical treatment of breast cancer was reliant solely on cytotoxic chemotherapy. However, over the past twenty years, treatment has evolved to a more target-directed approach. We now employ tailored therapy based on the presence or absence of receptors for estrogen, progesterone, and human epidermal growth factor 2 (HER2). We expect this trend to continue, as agents that use novel approaches to target HER2, as well as targeting different portions of the HER signaling pathway, are in various stages of development. Notably, pertuzumab, a humanized monoclonal antibody that binds to a different domain of the extracellular portion of the HER2 receptor than trastuzumab, was recently approved for use, as was lapatinib, a small-molecule tyrosine kinase inhibitor. Patients with triple negative breast cancer, particularly those with the BRCA mutation, have more limited treatment options and carry a worse prognosis than those who are hormone receptor positive. However, recent data has shown that PARP inhibitors may have significant anti-tumor effect in those with this subtype of breast cancer. Novel agents that inhibit mTOR, PI3K, the insulin-like growth factor, heat shock protein 90, and histone deacetylase have shown promise in phase I-III trials and offer exciting new possibilities for the treatment of this often fatal disease. As we are presented with an ever increasing number of treatment options, the timing and combinations of therapeutic agents used becomes ever more complex in the age of personalized care, but we are hopeful that ultimately this will lead to improved patient outcomes.

Original languageEnglish
Pages (from-to)117-132
Number of pages16
JournalJournal of Cancer
Volume4
Issue number2
DOIs
StatePublished - Aug 30 2013
Externally publishedYes

Fingerprint

Biological Therapy
Breast Neoplasms
Epidermal Growth Factor
Therapeutics
Triple Negative Breast Neoplasms
HSP90 Heat-Shock Proteins
Antibodies, Monoclonal, Humanized
Histone Deacetylases
Somatomedins
Progesterone Receptors
Phosphatidylinositol 3-Kinases
Estrogen Receptors
Protein-Tyrosine Kinases
Hormones
Drug Therapy
Mutation

Keywords

  • Biologics
  • Breast cancer
  • Chemotherapy
  • HER2
  • Novel therapeutics
  • PARP inhibitors.

ASJC Scopus subject areas

  • Oncology

Cite this

Tinoco, G., Warsch, S., Glück, S., Avancha, K., & Montero, A. J. (2013). Treating breast cancer in the 21st century: Emerging biological therapies. Journal of Cancer, 4(2), 117-132. https://doi.org/10.7150/jca.4925

Treating breast cancer in the 21st century : Emerging biological therapies. / Tinoco, Gabriel; Warsch, Sean; Glück, Stefan; Avancha, Kiran; Montero, Alberto J.

In: Journal of Cancer, Vol. 4, No. 2, 30.08.2013, p. 117-132.

Research output: Contribution to journalArticle

Tinoco, G, Warsch, S, Glück, S, Avancha, K & Montero, AJ 2013, 'Treating breast cancer in the 21st century: Emerging biological therapies', Journal of Cancer, vol. 4, no. 2, pp. 117-132. https://doi.org/10.7150/jca.4925
Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: Emerging biological therapies. Journal of Cancer. 2013 Aug 30;4(2):117-132. https://doi.org/10.7150/jca.4925
Tinoco, Gabriel ; Warsch, Sean ; Glück, Stefan ; Avancha, Kiran ; Montero, Alberto J. / Treating breast cancer in the 21st century : Emerging biological therapies. In: Journal of Cancer. 2013 ; Vol. 4, No. 2. pp. 117-132.
@article{daf10ecb648345d9833655ee399aaa81,
title = "Treating breast cancer in the 21st century: Emerging biological therapies",
abstract = "For many years, the medical treatment of breast cancer was reliant solely on cytotoxic chemotherapy. However, over the past twenty years, treatment has evolved to a more target-directed approach. We now employ tailored therapy based on the presence or absence of receptors for estrogen, progesterone, and human epidermal growth factor 2 (HER2). We expect this trend to continue, as agents that use novel approaches to target HER2, as well as targeting different portions of the HER signaling pathway, are in various stages of development. Notably, pertuzumab, a humanized monoclonal antibody that binds to a different domain of the extracellular portion of the HER2 receptor than trastuzumab, was recently approved for use, as was lapatinib, a small-molecule tyrosine kinase inhibitor. Patients with triple negative breast cancer, particularly those with the BRCA mutation, have more limited treatment options and carry a worse prognosis than those who are hormone receptor positive. However, recent data has shown that PARP inhibitors may have significant anti-tumor effect in those with this subtype of breast cancer. Novel agents that inhibit mTOR, PI3K, the insulin-like growth factor, heat shock protein 90, and histone deacetylase have shown promise in phase I-III trials and offer exciting new possibilities for the treatment of this often fatal disease. As we are presented with an ever increasing number of treatment options, the timing and combinations of therapeutic agents used becomes ever more complex in the age of personalized care, but we are hopeful that ultimately this will lead to improved patient outcomes.",
keywords = "Biologics, Breast cancer, Chemotherapy, HER2, Novel therapeutics, PARP inhibitors.",
author = "Gabriel Tinoco and Sean Warsch and Stefan Gl{\"u}ck and Kiran Avancha and Montero, {Alberto J.}",
year = "2013",
month = "8",
day = "30",
doi = "10.7150/jca.4925",
language = "English",
volume = "4",
pages = "117--132",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "2",

}

TY - JOUR

T1 - Treating breast cancer in the 21st century

T2 - Emerging biological therapies

AU - Tinoco, Gabriel

AU - Warsch, Sean

AU - Glück, Stefan

AU - Avancha, Kiran

AU - Montero, Alberto J.

PY - 2013/8/30

Y1 - 2013/8/30

N2 - For many years, the medical treatment of breast cancer was reliant solely on cytotoxic chemotherapy. However, over the past twenty years, treatment has evolved to a more target-directed approach. We now employ tailored therapy based on the presence or absence of receptors for estrogen, progesterone, and human epidermal growth factor 2 (HER2). We expect this trend to continue, as agents that use novel approaches to target HER2, as well as targeting different portions of the HER signaling pathway, are in various stages of development. Notably, pertuzumab, a humanized monoclonal antibody that binds to a different domain of the extracellular portion of the HER2 receptor than trastuzumab, was recently approved for use, as was lapatinib, a small-molecule tyrosine kinase inhibitor. Patients with triple negative breast cancer, particularly those with the BRCA mutation, have more limited treatment options and carry a worse prognosis than those who are hormone receptor positive. However, recent data has shown that PARP inhibitors may have significant anti-tumor effect in those with this subtype of breast cancer. Novel agents that inhibit mTOR, PI3K, the insulin-like growth factor, heat shock protein 90, and histone deacetylase have shown promise in phase I-III trials and offer exciting new possibilities for the treatment of this often fatal disease. As we are presented with an ever increasing number of treatment options, the timing and combinations of therapeutic agents used becomes ever more complex in the age of personalized care, but we are hopeful that ultimately this will lead to improved patient outcomes.

AB - For many years, the medical treatment of breast cancer was reliant solely on cytotoxic chemotherapy. However, over the past twenty years, treatment has evolved to a more target-directed approach. We now employ tailored therapy based on the presence or absence of receptors for estrogen, progesterone, and human epidermal growth factor 2 (HER2). We expect this trend to continue, as agents that use novel approaches to target HER2, as well as targeting different portions of the HER signaling pathway, are in various stages of development. Notably, pertuzumab, a humanized monoclonal antibody that binds to a different domain of the extracellular portion of the HER2 receptor than trastuzumab, was recently approved for use, as was lapatinib, a small-molecule tyrosine kinase inhibitor. Patients with triple negative breast cancer, particularly those with the BRCA mutation, have more limited treatment options and carry a worse prognosis than those who are hormone receptor positive. However, recent data has shown that PARP inhibitors may have significant anti-tumor effect in those with this subtype of breast cancer. Novel agents that inhibit mTOR, PI3K, the insulin-like growth factor, heat shock protein 90, and histone deacetylase have shown promise in phase I-III trials and offer exciting new possibilities for the treatment of this often fatal disease. As we are presented with an ever increasing number of treatment options, the timing and combinations of therapeutic agents used becomes ever more complex in the age of personalized care, but we are hopeful that ultimately this will lead to improved patient outcomes.

KW - Biologics

KW - Breast cancer

KW - Chemotherapy

KW - HER2

KW - Novel therapeutics

KW - PARP inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84877814639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877814639&partnerID=8YFLogxK

U2 - 10.7150/jca.4925

DO - 10.7150/jca.4925

M3 - Article

C2 - 23386910

AN - SCOPUS:84877814639

VL - 4

SP - 117

EP - 132

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 2

ER -